Progenika devotes most of its R&D resources to the identification and validation of genetic biomarkers associated to human diseases, as well as to the development of new diagnostic methods for their detection. Progenika participates regularly in R & D projects and clinical validations in collaboration with research centers, universities, hospitals and European companies involved in:
(1) Identifying gene products related to human diseases in order to develop specific therapies.
(2) Developing technologies for the diagnosis and prognosis of complex diseases with a genetic component.
(3) Identifying gene expression profiles that characterize and allow for the prediction of toxicity by candidate drugs. Human diseases such as multiple sclerosis, osteoporosis, rheumatoid arthritis or prostate cancer, among others, represent the core of the investigation activity.
Progenika also participates in pharmacogenomics and toxicogenomics studies for the in vitro and in vivo analysis of the molecular mechanisms of action of drugs under development and for the evaluation of their potential toxicity.